An interventional study of Mentee encounters in Ovarian Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Abramson Cancer Center at Penn Medicine · Not applicable, Interventional, and Health services research
The goal of this study is to learn if peer ambassador support will increase clinical trial enrollment in patients with ovarian cancer.
Participants will participate in a peer ambassador program where a patient ambassador (mentor) will be paired with a mentee. The patient ambassador will be a patient with history of cancer who has participated in a clinical trial and can serve as an ambassador to facilitate discussions regarding education and awareness of clinical trials.
Participants will participate in a peer ambassador program where a patient ambassador (mentor) will be paired with a mentee. The patient ambassador will be a patient with history of cancer who has participated in a clinical trial and can serve as an ambassador to facilitate discussions regarding education and awareness of clinical trials. This discussion will potentially assist mentees to make informed decisions about their engagement in discussing clinical trials, looking for clinical trials, and desire and acceptance of clinical trials. This will also allow ambassadors to gain information about perceived barriers regarding clinical trials.
This study will be a multi-institutional prospective cohort study conducted at Penn and Hopkins. We seek to identify approximately 10 patient ambassadors, who will be trained to lead 1:1 discussion with patient mentees. Each ambassador will be paired with up to 10 mentees. Each ambassador-mentee pairing will have 1-2 encounters (meetings) over the course of 12 months.
2,763 studies on the registry are indexed under Ovarian Neoplasms; 735 are open to participants now.
This study's planned enrollment of 125 is above the median of 59 across 2,079 interventional studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Abramson Cancer Center at Penn Medicine is the lead sponsor of 460 studies on the registry; 88 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 14 (42%) have results posted.
Counted across the registry records on this site, refreshed daily.
Mentees Inclusion Criteria:
Ambassadors Inclusion Criteria:
Mentees will participate in an enrollment session, discussion session with an ambassador, close out session, and 12 month clinical care follow up during which electronic medical records will be reviewed to assess whether mentees are subsequently screened or enrolled in clinical trials.
Other: Mentee encounters
Mentee meetings as previously described
Attitude about enrolling in trials
Participants' attitudes about enrolling in trials will be assessed through the Attitudes Toward Cancer Trials Scales (ACTS). Scores will range from 18-126. The difference between pre and post intervention scores will be assessed.
Time frame: 12 months from enrollment
Intent to Enroll in Trials
Participants' intent to enroll in trials will be assessed through a previously validated Attitudes and Intention to Enroll in Therapeutic Clinical Trials (AIET) instrument. Responses will range from yes or no.
Time frame: 12 months from enrollment
Mentee knowledge regarding clinical trials before and after discussion sessions
This will be assessed using a knowledge of clinical trials questionnaire. Scores will range from 0-12. The difference between pre and post intervention scores will be assessed.
Time frame: Within 12 weeks of completing all sessions
Feasibility of this ambassador program
Feasibility of this ambassador program will be assessed using the Feasibility of Intervention Measure (FIM). Scores will range from 1-5.
Time frame: 12 months from study start
Acceptability of this ambassador program
Acceptability will be assessed using the Acceptability of Intervention Measure (AIM). Scores will range from 1-5.
Time frame: 12 months from study start
Proportion of mentees in this program who enrolled onto a clinical trial
Mentees will be followed for 12 months and it will be documented if they enroll in a clinical trial. The percent of mentees who enroll in a clinical trial will be calculated.
Time frame: 12 months from study start
Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.
Of 253 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 11 months is below that.
Counting every sponsor, half of 259 studies reached it within 49 months; a quarter within 24 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine →